Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 26, 2018 - Issue 2
Submit an article Journal homepage
446
Views
33
CrossRef citations to date
0
Altmetric
Letter to the Editor

Bilateral Anterior Uveitis Associated with Nivolumab Therapy

Justin KarlinDepartment of Ophthalmology, University of Virginia, Charlottesville, Virginia, USA
, MD, MSc,
Ryan GentzlerDepartment of Hematology and Oncology, University of Virginia, Charlottesville, Virginia, USA
, MD &
Jeffrey GolenDepartment of Ophthalmology, University of Virginia, Charlottesville, Virginia, USACorrespondence[email protected]
, MD
Pages 283-285 | Received 14 May 2016, Accepted 18 Jul 2016, Published online: 06 Sep 2016

REFERENCES

  • Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
  • United States Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, June 14, 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed August 8, 2016.
  • London NJ, Garg SJ, Moorthy RS, et al. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:43.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
  • Keir M, Butte M, Freeman F, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
  • D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95–102.
  • Borghaei H, Brahmer J. Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med. 2016;374:493–494.
  • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387:1540–1550.
  • Zhou R, Caspi RR. Ocular immune privilege. F1000 Biol Rep. 2010;2:ii.
  • Sugita S, Usui Y, Horie S, et al. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci. 2009;50:2862–2870.
  • Lee DJ, Taylor AW. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol. 2015;97:1101–1109.
  • de Velasco G, Bermas B, Choueiri TK. Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol. 2016;68:556–557.
  • Abu Samra K, Valdes-Navarro M, Lee S. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26:e46–e48.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.